Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NC-758 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| NC-758 (Anti amyloidotic [Aß] agent) | DRUG | - |
Inclusion Criteria * Patients must be 55 years of age or older. * Males and females. Females must be of non-childbearing potential (i.e. surgically sterilized or at least one year post-menopausal). * Diagnosis of possible or probable CAA based on the Boston Criteria for Diagnosis of CAA-Related Hem...
Top 20 of 24 competitors
NC-758 is an investigational small molecule being developed for the treatment of stroke, specifically for patients with lobar hemorrhage related to cerebral amyloid angiopathy. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
NC-758 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The drug is currently in Phase 2 clinical development for the treatment of stroke.
NC-758 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed, and the drug remains under investigation for the treatment of stroke.
NC-758 has one completed Phase 2 clinical trial, identified as NCT00056238, titled "Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy." The trial enrolled 30 participants in the United States and was a randomized, double-blind study.
NC-758 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of stroke. A Phase 2 clinical trial has been completed, but the drug has not yet received regulatory approval.